PO.TB10.14 · 肿瘤生物学
非流行区EBV相关鼻咽癌肿瘤内微生物群的特征分析
Characterization of the intratumoral microbiota in non endemic EBV associated nasopharyngeal carcinoma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
Epstein-Barr病毒(EBV)相关鼻咽癌(NPC)是一种起源于鼻咽黏膜衬里的上皮性恶性肿瘤。在流行区(EA),即东亚和东南亚,EBV相关NPC的发病率较高。微生物群驻留于包括鼻咽在内的上呼吸道。因此,已对EA地区EBV相关NPC中的肿瘤内微生物群(ITM)进行了特征分析,其中Corynebacterium和Staphylococcus是最主要的分类单元。目前,非流行区(NEA)NPC的ITM谱仍未被探索。我们假设NEA NPC中的ITM与肿瘤生物学相关。在我们此前的NEA EBV相关NPC研究中,我们将患者分为三个转录簇(Cl1:免疫活跃型;Cl2:防御应答型;Cl3:增殖型),其中Cl3预后最差。因此,本研究依据我们的分簇模型探究ITM组成。我们收集了94例NEA NPC EBV相关病例的福尔马林固定石蜡包埋(FFPE)样本。使用miRneasy试剂盒(Qiagen)提取总RNA,使用QuantSeq 3' mRNA(Lexogen)构建文库,并在NextSeq500(Illumina)上测序。ITM组成和免疫细胞解卷积(xCell)由RNAseq数据推断。进行了各簇间的差异丰度分析(LEfSe)以及免疫细胞群与差异丰度分类单元之间的相关性分析。为验证RNAseq结果并评估空间共定位模式,对每个簇选取一个代表性病例进行了空间与宏转录组学(SMT)分析(Stereoseq OMNI for FFPE, STOmics)。在我们的NEA队列中共检测到297个细菌分类单元。LEfSe比较显示,Bacteroidota和Pseudomonadota在Cl1相较Cl2中富集,而Bacillaceae在Cl2中占主导。Actinomycetota在Cl1中比Cl3更常见。相关性分析显示,在各簇比较中发现的大多数差异丰度分类单元与成纤维细胞和基质评分呈正相关,而与CD8+和CD4+ T细胞群呈负相关。SMT分析证实了肿瘤内细菌的表达:Cl1和Cl2相较EBV表现出更高的细菌比例(后者分别在14.6%和23.6%中表达),而Cl3同时显示细菌和EBV信号,且以EBV表达为主(52.5%)。SMT分析正在进行中,以揭示免疫细胞、肿瘤内细菌和EBV之间的共表达模式。本研究首次对NEA EBV相关NPC中的ITM进行了特征分析。在预后最差的亚组Cl3中检测到较高的EBV表达,提示EBV与特定细菌分类单元在NPC发病机制中可能存在协同相互作用。这些发现凸显了微生物组对肿瘤微环境的影响,并支持其作为NEA EBV相关NPC生物标志物的潜力。
查看英文原文 English abstract
Epstein-Barr virus (EBV) related nasopharyngeal carcinoma (NPC) is an epithelial malignancy arising from the nasopharyngeal mucosal lining. A high incidence of EBV related NPC is recorded in endemic areas (EA), East and Southeast Asia. Microbiota resides the upper respiratory tract including nasopharynx. Thus, intratumoral microbiota (ITM) in EA EBV related NPC has been characterized with Corynebacterium and Staphylococcus being the most predominant taxa. Currently, ITM profile in NPC remain unexplored in non endemic area (NEA). We hypothesized that the ITM in NEA NPC is associated to tumor biology. In our previously NEA EBV related NPC study, we stratified patients into three transcriptional clusters (Cl1: immune active; Cl2: defense response; Cl3: proliferative), with Cl3 displaying the poorest prognosis. Hence, the present work investigates the ITM composition according to our clusters' model. Formalin-fixed paraffin embedded (FFPE) samples from 94 NEA NPC EBV related cases were collected. Total RNA was extracted using miRneasy kit (Qiagen) and libraries were generated using QuantSeq 3' mRNA (Lexogen) and sequenced on the NextSeq500 (Illumina). The ITM composition and immune cell deconvolution (xCell) were inferred from RNAseq data. Differential abundance analyses (LEfSe) among clusters and correlation analyses between immune cells populations and differentially abundant taxa were conducted. To validate the RNAseq findings and assess spatial colocalization patterns, spatial and metatranscriptomics (SMT) (Stereoseq OMNI for FFPE, STOmics) was performed on one representative case per cluster. 297 bacterial taxa were detected in our NEA cohort. LEfSe comparisons showed that Bacteroidota and Pseudomonadota were enriched in Cl1 vs Cl2, while Bacillaceae dominated in Cl2. Actinomycetota was more prevalent in Cl1 vs Cl3. Correlation analyses showed that most differentially abundant taxa, found in clusters' comparison, were positively associated with fibroblast and stroma score and inversely correlated with CD8+ and CD4+ T cell populations. SMT profiling confirmed intratumoral bacteria expression: Cl1 and Cl2 exhibited higher bacterial proportion in respect to EBV (the latter expressed in 14.6% and 23.6%, respectively), while Cl3 displayed both bacterial and EBV signals, with a predominant EBV expression (52.5%). SMT analyses is ongoing to disclose co expression patterns between immune cells, intratumoral bacteria and EBV. This study provides the first characterization of the ITM in NEA EBV related NPC. Higher EBV expression was detected in Cl3, the subgroup associated with the poorest prognosis, suggesting a possible synergistic interplay between EBV and specific bacterial taxa in the NPC pathogenesis. These findings highlight the impact of the microbiome on the tumor microenvironment and support its potential as biomarker in NEA EBV related NPC.
利益披露 Disclosure
D. Lenoci, None..
F. Rossignoli, None..
A. G. Licata, None..
M. Lucchetta, None..
I. Rolli, None..
M. Ficorilli, None..
A. Manocchio, None..
N. Crippa, None..
W. Ferrari Bravo, None..
F. Manoni, None..
M. Zucchini, None..
F. Taverna, None..
S. Cavalieri, None.
L. Licitra,
AstraZeneca Other, institutional grants and personal fees.
Bristol Myers Squibb Other, institutional grants and personal fees.
Boehringer Ingelheim Other, institutional grants and personal fees.
Debiopharm International SA Other, institutional grants and personal fees.
Eisai Other, institutional grants and personal fees.
Novartis Other, institutional grants and personal fees.
Roche Other, institutional grants and personal fees.
Celgene International Other, institutional grants.
Exelixis Other, institutional grants.
Hoffmann-La Roche Other, institutional grants.
IRX Therapeutics Other, institutional grants.
Medpace Other, institutional grants.
Merck Serono Other, institutional grants.
Pfizer Other, institutional grants.
Sobi Other, personal fees.
Ipsen Other, personal fees.
Incyte Biosciences Italy SRL Other, personal fees.
Doxa Pharma Other, personal fees.
Amgen Other, personal fees.
Nanobiotics SA Other, personal fees.
L. De Cecco, None..
S. Alfieri, None.